Advanced Biomed Inc. (ADVB) is a Medical Specialities company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for ADVB, including 1 SEC filing. The most recent was published Oct 13, 2026.
Financial highlights
Full financials- Revenue, FY2026
- $127.6K
- Net income, FY2026
- $6.68M
- Net margin
- 5231.3%
- Cash
- $385.5K
For fiscal 2026 (ended Jun 30, 2026), from SEC filings. Not investment advice.
News · 26 weeks8-100%
2026-05-172026-11-08
Mix390d
- Insider1(33%)
- Other1(33%)
- SEC Filings1(33%)
Activity · 52 weeks2725 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-K filed by Advanced Biomed Inc.10-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECSEC Form NT 10-K filed by Advanced Biomed Inc.NT 10-K - Advanced Biomed Inc. (0001941029) (Filer)
- INSIDERLarge owner Pau Hung To disposed of $84,588,000,000 worth of Common Stock par vlaue $0.001 (176,225 units at $480,000.00), closing all direct ownership in the company (SEC Form 4)4 - Advanced Biomed Inc. (0001941029) (Issuer)
- SECSEC Form RW filed by Advanced Biomed Inc.RW - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECSEC Form DEF 14A filed by Advanced Biomed Inc.DEF 14A - Advanced Biomed Inc. (0001941029) (Filer)
- SECSEC Form 10-Q filed by Advanced Biomed Inc.10-Q - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Leadership Update8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Other Events8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- PRAdvanced Biomed Inc. Announces 1 for 20 Share ConsolidationTainan City, Taiwan, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (NASDAQ:ADVB) (the "Company" or "Advanced Biomed"), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced a reverse stock split of the Company's issued and outstanding common stock at a ratio of 1 for 20 shares (the "Reverse Split"), which will take effect at the open of The Nasdaq Stock Market ("Nasdaq") on February 20, 2026. In accordance with Section 78.320.2 of the Nevada Revised Statutes, on January 12, 2026, the holders of a majority of the outstanding voting power of the Company approved by written co
- SECSEC Form 10-Q filed by Advanced Biomed Inc.10-Q - Advanced Biomed Inc. (0001941029) (Filer)
- PRAdvanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug DiscoveryTainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (NASDAQ:ADVB) (the "Company", "Advanced Biomed"), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the Company has entered into a clinical research collaboration agreement (the "Agreement") with Chi‑Mei Medical Center to initiate a 120‑case feasibility study designed to evaluate the predictive accuracy of the Company's A+PerfusC™, a perfusion-based 3D cell culture in a compact incubator designed to replicate human physiological conditions in vitro. The feasibility study is a non‑interventional clinical resea
- SECAmendment: Advanced Biomed Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K/A - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECSEC Form DEF 14C filed by Advanced Biomed Inc.DEF 14C - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECSEC Form PRE 14C filed by Advanced Biomed Inc.PRE 14C - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
ADVB FAQ
9 questionsWhat is the latest news on ADVB?
In the last 30 days Quantisnow tracked 1 wire item for ADVB: 1 SEC filing. The most recent was published on October 13, 2026.What is ADVB revenue?
Advanced Biomed Inc. (ADVB) reported $127.6K of revenue for fiscal 2026 (ended Jun 30, 2026).Is ADVB profitable?
Yes. Advanced Biomed Inc. earned $6.68M in net income for fiscal 2026 (ended Jun 30, 2026), a net margin of 5231.3%.How much cash and debt does ADVB have?
Advanced Biomed Inc. reported $385.5K in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does ADVB stock trade?
Advanced Biomed Inc. (ADVB) is listed on NASDAQ.What sector and industry is ADVB in?
Advanced Biomed Inc. operates in the Health Care sector, Medical Specialities industry.When did Advanced Biomed Inc. go public?
Advanced Biomed Inc. (ADVB) completed its IPO in 2025.What companies are similar to ADVB?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.), NTRA (Natera Inc.). Compare ADVB side-by-side with any of them on Quantisnow.How can I track ADVB on Quantisnow?
Quantisnow aggregates Advanced Biomed Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADVB to receive live email and push alerts on every new disclosure.